ArticleCase reports in oncology
Synchronous Double Primary Malignancy of Non-Small Cell Lung Cancer and Glioblastoma: A Case Report and Literature Review.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neurosurgical Resection for De Novo Brain Metastases from Non-Small Cell Lung Cancer: Real-World Evidence for Multidisciplinary Decision-Making.Journal of clinical medicine · 2026Article
- Regression of a Non-Irradiated Lung Adenocarcinoma During Glioblastoma-Directed Chemoradiotherapy: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Primary glioblastoma mimicking brain metastasis in ALK-positive lung adenocarcinoma: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and has a propensity to metastasize to the brain. It is incredibly difficult to distinguish between a primary brain lesions and a solitary metastasis from distant occult disease using current imaging techniques. Further, complications arise from the shifting paradigm in how medicine views NSCLC brain metastasis due to contemporary nonsurgical curative treatments and the recent increase in the number of multiple primary malignancy (MPM) diagnoses associated with NSCLC. There is a dearth of reports regarding synchronous double primary malignancies involving separate lung and brain pathologies. Importantly, understanding the underlying cancer etiology is necessary for efficacious treatment strategy. Case Presentation: A 65-year-old white male patient presented with node-positive NSCLC and a solitary intracranial lesion. The lung mass responded favorably to chemoradiotherapy while the brain lesion continued to progress despite stereotactic radiosurgery treatment. Subsequent resection of the brain lesion, conducted 8 months after initial presentation, surprisingly revealed a second primary cancer diagnosis of glioblastoma (GB). Unfortunately, despite revision of systemic therapeutic strategy, the patient continued to progress through treatment and ultimately died 16 months after the initial diagnosis. Conclusion: Herein is the third report regarding synchronous double primary malignancies involving non-small cell lung cancer (NSCLC) and GB. This report of an assumed metastatic NSCLC patient with a solitary brain lesion, history of smoking, and COPD underscores the need for pathological confirmation of all new presentations of metastatic disease via biopsy and highlights the importance of including the possibility of a second primary in the differential diagnosis. Additional reports of NSCLC and synchronous solitary brain lesions are needed to further elucidate pertinent patient characteristics and better inform clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.